Hologic's (HOLX) "Outperform" Rating Reiterated at William Blair

Hologic (NASDAQ:HOLX - Get Free Report)'s stock had its "outperform" rating reaffirmed by stock analysts at William Blair in a note issued to investors on Monday,RTT News reports.

A number of other analysts have also recently weighed in on the stock. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a report on Thursday, November 14th. BNP Paribas upgraded shares of Hologic to a "strong-buy" rating in a research report on Tuesday, December 10th. Jefferies Financial Group began coverage on shares of Hologic in a research report on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price on the stock. Leerink Partners lowered their target price on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Finally, Mizuho lowered their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a research report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $88.92.

Hologic Stock Down 2.0 %

NASDAQ:HOLX traded down $1.41 during mid-day trading on Monday, hitting $70.29. The stock had a trading volume of 3,100,719 shares, compared to its average volume of 2,138,960. The stock has a 50-day simple moving average of $75.88 and a two-hundred day simple moving average of $78.55. The company has a market capitalization of $15.95 billion, a PE ratio of 21.11, a PEG ratio of 2.32 and a beta of 0.97. Hologic has a twelve month low of $69.46 and a twelve month high of $84.67. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The firm had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm's revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.89 earnings per share. On average, equities research analysts anticipate that Hologic will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.75% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. raised its stake in Hologic by 0.3% in the 3rd quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider's stock valued at $3,967,000 after purchasing an additional 130 shares during the last quarter. Covestor Ltd grew its holdings in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider's stock valued at $56,000 after buying an additional 133 shares during the period. First Horizon Advisors Inc. grew its holdings in Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Empirical Finance LLC grew its holdings in Hologic by 1.8% in the 3rd quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider's stock valued at $690,000 after buying an additional 147 shares during the period. Finally, Wedmont Private Capital grew its holdings in Hologic by 3.7% in the 3rd quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider's stock valued at $361,000 after buying an additional 162 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.